STOCK TITAN

[Form 4] Amedisys Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Amedisys Inc. (AMED) – Form 4 filing overview

Director Bruce D. Perkins reported one transaction dated 07/01/2025. Using transaction code “G” (gift), Perkins transferred 105 shares of Amedisys common stock at a stated price of $0. Following the gift, the director’s direct beneficial ownership stands at 23,992 shares.

The filing does not disclose any derivative security activity and contains no additional explanatory remarks beyond the standard signature block.

  • Size of transaction: ~0.4 % of the director’s post-transaction holdings
  • Insider relationship: Director (non-executive)
  • Ownership form: Direct

No other material financial data, earnings information, or strategic commentary is included in this short Form 4.

Amedisys Inc. (AMED) – Panoramica della comunicazione Form 4

Il direttore Bruce D. Perkins ha segnalato una transazione datata 01/07/2025. Utilizzando il codice transazione “G” (dono), Perkins ha trasferito 105 azioni ordinarie di Amedisys a un prezzo dichiarato di $0. Dopo questo trasferimento a titolo gratuito, la proprietà diretta del direttore ammonta a 23.992 azioni.

La comunicazione non riporta alcuna attività relativa a strumenti derivati e non contiene ulteriori commenti esplicativi oltre al blocco standard per la firma.

  • Dimensione della transazione: circa lo 0,4% delle azioni detenute dal direttore dopo la transazione
  • Relazione dell’insider: Direttore (non esecutivo)
  • Forma di proprietà: Diretta

Non sono inclusi altri dati finanziari rilevanti, informazioni sugli utili o commenti strategici in questo breve modulo Form 4.

Amedisys Inc. (AMED) – Resumen del formulario 4

El director Bruce D. Perkins reportó una transacción con fecha 01/07/2025. Usando el código de transacción “G” (regalo), Perkins transfirió 105 acciones ordinarias de Amedisys a un precio declarado de $0. Tras esta donación, la propiedad directa del director queda en 23,992 acciones.

El reporte no revela ninguna actividad con valores derivados y no contiene comentarios adicionales más allá del bloque estándar para firmas.

  • Tamaño de la transacción: ~0.4 % de las acciones en posesión del director después de la transacción
  • Relación del insider: Director (no ejecutivo)
  • Forma de propiedad: Directa

No se incluyen otros datos financieros relevantes, información sobre ganancias ni comentarios estratégicos en este breve Formulario 4.

Amedisys Inc. (AMED) – Form 4 제출 개요

이사 Bruce D. Perkins2025년 7월 1일자로 한 건의 거래를 보고했습니다. 거래 코드 “G” (증여)를 사용하여 Perkins는 Amedisys 보통주 105주를 명시된 가격 $0에 이전했습니다. 증여 후 이사의 직접 보유 주식 수는 23,992주입니다.

제출 서류에는 파생상품 관련 활동이 없으며, 표준 서명 블록 외 추가 설명은 포함되어 있지 않습니다.

  • 거래 규모: 거래 후 이사의 보유 주식의 약 0.4%
  • 내부자 관계: 이사 (비임원)
  • 소유 형태: 직접 보유

이 짧은 Form 4에는 기타 중요한 재무 데이터, 수익 정보 또는 전략적 논평이 포함되어 있지 않습니다.

Amedisys Inc. (AMED) – Aperçu du dépôt Formulaire 4

Le directeur Bruce D. Perkins a déclaré une transaction datée du 01/07/2025. En utilisant le code de transaction « G » (don), Perkins a transféré 105 actions ordinaires d’Amedisys à un prix déclaré de 0 $. Suite à ce don, la propriété directe du directeur s’élève à 23 992 actions.

Le dépôt ne révèle aucune activité liée à des titres dérivés et ne contient pas d’autres remarques explicatives au-delà du bloc de signature standard.

  • Taille de la transaction : environ 0,4 % des avoirs du directeur après la transaction
  • Relation de l’initié : Directeur (non exécutif)
  • Forme de propriété : Directe

Aucune autre donnée financière importante, information sur les bénéfices ou commentaire stratégique n’est incluse dans ce bref Formulaire 4.

Amedisys Inc. (AMED) – Übersicht der Form 4-Meldung

Direktor Bruce D. Perkins meldete eine Transaktion vom 01.07.2025. Mit dem Transaktionscode „G“ (Schenkung) übertrug Perkins 105 Aktien der Amedisys-Stammaktien zu einem angegebenen Preis von 0 $. Nach der Schenkung beträgt das direkte wirtschaftliche Eigentum des Direktors 23.992 Aktien.

Die Meldung enthält keine Angaben zu Derivaten und keine weiteren erläuternden Bemerkungen über den Standard-Unterschriftsblock hinaus.

  • Transaktionsgröße: ca. 0,4 % der nach der Transaktion gehaltenen Aktien des Direktors
  • Insider-Beziehung: Direktor (nicht geschäftsführend)
  • Eigentumsform: Direkt

Weitere wesentliche Finanzdaten, Gewinninformationen oder strategische Kommentare sind in diesem kurzen Form 4 nicht enthalten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small, non-monetary gift of 105 AMED shares; immaterial to company valuation.

The transaction is coded “G,” indicating a gift rather than an open-market sale. With only 105 shares transferred—roughly 0.4 % of the insider’s 24 k-share position—the filing does not suggest bearish sentiment or raise liquidity concerns. There is no cash consideration and no derivative involvement, so the event has negligible impact on float, insider ownership trends, or valuation models. I classify this as routine compliance reporting.

TL;DR: Routine insider gift; governance signal neutral.

Gifts are normally made for estate or charitable planning and do not imply strategic intent. Perkins remains well above typical ownership guidelines for directors, maintaining nearly 24 k shares. The absence of multiple transactions or derivative hedges reinforces the neutral signal. From a governance standpoint, no red flags or positive catalysts emerge.

Amedisys Inc. (AMED) – Panoramica della comunicazione Form 4

Il direttore Bruce D. Perkins ha segnalato una transazione datata 01/07/2025. Utilizzando il codice transazione “G” (dono), Perkins ha trasferito 105 azioni ordinarie di Amedisys a un prezzo dichiarato di $0. Dopo questo trasferimento a titolo gratuito, la proprietà diretta del direttore ammonta a 23.992 azioni.

La comunicazione non riporta alcuna attività relativa a strumenti derivati e non contiene ulteriori commenti esplicativi oltre al blocco standard per la firma.

  • Dimensione della transazione: circa lo 0,4% delle azioni detenute dal direttore dopo la transazione
  • Relazione dell’insider: Direttore (non esecutivo)
  • Forma di proprietà: Diretta

Non sono inclusi altri dati finanziari rilevanti, informazioni sugli utili o commenti strategici in questo breve modulo Form 4.

Amedisys Inc. (AMED) – Resumen del formulario 4

El director Bruce D. Perkins reportó una transacción con fecha 01/07/2025. Usando el código de transacción “G” (regalo), Perkins transfirió 105 acciones ordinarias de Amedisys a un precio declarado de $0. Tras esta donación, la propiedad directa del director queda en 23,992 acciones.

El reporte no revela ninguna actividad con valores derivados y no contiene comentarios adicionales más allá del bloque estándar para firmas.

  • Tamaño de la transacción: ~0.4 % de las acciones en posesión del director después de la transacción
  • Relación del insider: Director (no ejecutivo)
  • Forma de propiedad: Directa

No se incluyen otros datos financieros relevantes, información sobre ganancias ni comentarios estratégicos en este breve Formulario 4.

Amedisys Inc. (AMED) – Form 4 제출 개요

이사 Bruce D. Perkins2025년 7월 1일자로 한 건의 거래를 보고했습니다. 거래 코드 “G” (증여)를 사용하여 Perkins는 Amedisys 보통주 105주를 명시된 가격 $0에 이전했습니다. 증여 후 이사의 직접 보유 주식 수는 23,992주입니다.

제출 서류에는 파생상품 관련 활동이 없으며, 표준 서명 블록 외 추가 설명은 포함되어 있지 않습니다.

  • 거래 규모: 거래 후 이사의 보유 주식의 약 0.4%
  • 내부자 관계: 이사 (비임원)
  • 소유 형태: 직접 보유

이 짧은 Form 4에는 기타 중요한 재무 데이터, 수익 정보 또는 전략적 논평이 포함되어 있지 않습니다.

Amedisys Inc. (AMED) – Aperçu du dépôt Formulaire 4

Le directeur Bruce D. Perkins a déclaré une transaction datée du 01/07/2025. En utilisant le code de transaction « G » (don), Perkins a transféré 105 actions ordinaires d’Amedisys à un prix déclaré de 0 $. Suite à ce don, la propriété directe du directeur s’élève à 23 992 actions.

Le dépôt ne révèle aucune activité liée à des titres dérivés et ne contient pas d’autres remarques explicatives au-delà du bloc de signature standard.

  • Taille de la transaction : environ 0,4 % des avoirs du directeur après la transaction
  • Relation de l’initié : Directeur (non exécutif)
  • Forme de propriété : Directe

Aucune autre donnée financière importante, information sur les bénéfices ou commentaire stratégique n’est incluse dans ce bref Formulaire 4.

Amedisys Inc. (AMED) – Übersicht der Form 4-Meldung

Direktor Bruce D. Perkins meldete eine Transaktion vom 01.07.2025. Mit dem Transaktionscode „G“ (Schenkung) übertrug Perkins 105 Aktien der Amedisys-Stammaktien zu einem angegebenen Preis von 0 $. Nach der Schenkung beträgt das direkte wirtschaftliche Eigentum des Direktors 23.992 Aktien.

Die Meldung enthält keine Angaben zu Derivaten und keine weiteren erläuternden Bemerkungen über den Standard-Unterschriftsblock hinaus.

  • Transaktionsgröße: ca. 0,4 % der nach der Transaktion gehaltenen Aktien des Direktors
  • Insider-Beziehung: Direktor (nicht geschäftsführend)
  • Eigentumsform: Direkt

Weitere wesentliche Finanzdaten, Gewinninformationen oder strategische Kommentare sind in diesem kurzen Form 4 nicht enthalten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PERKINS BRUCE D

(Last) (First) (Middle)
3854 AMERICAN WAY, SUITE A

(Street)
BATON ROUGE LA 70816

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AMEDISYS INC [ AMED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 G 105 D $0 23,992 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Jennifer Guckert Griffin, pursuant to a power of attorney 07/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Amedisys (AMED) shares did Director Bruce D. Perkins transfer?

Perkins gifted 105 common shares on 07/01/2025.

What is the director’s remaining ownership after the transaction?

Following the gift, Perkins directly owns 23,992 AMED shares.

Was the transaction an open-market sale or purchase?

No. It was coded “G” for gift, indicating no market sale or purchase.

Did the Form 4 report any derivative security activity?

No derivative securities were acquired, disposed of, or held according to the filing.

Does this Form 4 filing materially affect Amedisys’ share count?

No. The 105-share gift is immaterial relative to Amedisys’ total outstanding shares.
Amedisys Inc

NASDAQ:AMED

AMED Rankings

AMED Latest News

AMED Latest SEC Filings

AMED Stock Data

3.15B
32.18M
2.09%
91.58%
8.81%
Medical Care Facilities
Services-home Health Care Services
Link
United States
BATON ROUGE